• Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms

  • Mar 31 2025
  • Duración: 18 m
  • Podcast

Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • CAR T-cell therapy has revolutionized the lymphoma treatment landscape in recent years. In this episode, we delve into cutting-edge CAR strategies being investigated for lymphoma, including allogeneic products, trispecific CARs, and more. Key highlights include insights into CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T-cell product. This episode also covers studies of trispecific CAR T-cells targeting CD19, CD20, and CD22.

    Stay tuned to learn more about these promising approaches from experts Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, Armin Ghobadi, MD, Washington University School of Medicine, St. Louis, MO, Evandro Bezerra, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Valentín Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain.
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles